Shareholders Approve Reverse Stock Split to Maintain NASDAQ Listing

summarizeSummary

XORTX Therapeutics Inc. shareholders have approved a share consolidation of up to 5:1, a critical step to meet NASDAQ's minimum bid price requirement and avoid delisting.

check_boxKey Events

• Share Consolidation Approved

  Shareholders authorized a reverse stock split on a basis of up to five (5) pre-consolidation shares for every one (1) post-consolidation share.

• NASDAQ Compliance Critical

  The consolidation is intended to maintain compliance with NASDAQ's continual listing requirements, specifically the $1.00 minimum bid price, and a condition to trade above $1.00 for 10 days by April 13, 2026.

• Pending Exchange Approval

  The consolidation is awaiting approval from the TSX Venture Exchange before it can be implemented by the Board of Directors.

• Follows Going Concern Warning

  This action comes shortly after the company disclosed a "going concern" warning from its auditor and a material weakness in internal controls in its recent 20-F filing on March 20, 2026.

auto_awesomeAnalysis

This shareholder approval of a reverse stock split is a crucial, albeit reactive, measure for XORTX Therapeutics to maintain its NASDAQ listing, especially given the recent "going concern" warning in its annual report. While preventing immediate delisting, reverse splits often signal underlying financial distress and can be viewed negatively by investors, potentially leading to further share price volatility. Investors should monitor the actual implementation date and the company's progress in addressing its fundamental financial challenges.